Opdivo plus chemo improves event-free survival in NSCLC patients
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
Read More
Tag: NSCLC
MHRA backs Merck’s MET inhibitor Tepmetko
Conditional marketing authorisation granted for patients with advanced NSCLC with METex14 skipping alterations
Read More
Amgen reveals new combination data for KRAS inhibitor
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens
Read More
Amgen to collab with Verastem on KRAS combination treatment
Agreement will evaluate Verastem’s dual RAF/MEK inhibitor with Amgen’s KRAS G12C inhibitor
Read More
Sanofi/Regeneron’s Libtayo hits the mark in first-line NSCLC
Positive data presented at the 2021 ESMO virtual congress
Read More
MHRA approves Amgen’s Lumykras under Project Orbis
Project Orbis is an international collaborative programme between the FDA and worldwide regulatory agencies
Read More
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
The positive opinion has been issued via the MHRA’s early access the medicine (EAMS) scheme
Read More
FDA approves Janssen’s Rybrevant
First targeted treatment authorised in the US for NSCLC patients with EGFR exon 20 insertion mutations
Read More
Imfinzi, tremelimumab combo boosts survival in lung cancer
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
Read More
AZ’ Tagrisso first to win MHRA approval under Project Orbis
Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
Read More
Tecentriq approved for first-line metastatic NSCLC
Checkpoint inhibitor specifically approved for patients with high PD-L1 expression
Read More
NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
